Vaxcell-Bio Financial Statements From 2010 to 2025
| 323990 Stock | KRW 9,380 60.00 0.64% |
Check Vaxcell-Bio Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxcell-Bio Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Vaxcell-Bio financial statements analysis is a perfect complement when working with Vaxcell-Bio Therapeutics Valuation or Volatility modules.
Vaxcell-Bio |
Vaxcell Bio Therapeutics Co Company Gross Profit Analysis
Vaxcell-Bio Therapeutics' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current Vaxcell-Bio Therapeutics Gross Profit | (5.39 M) |
Most of Vaxcell-Bio Therapeutics' fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vaxcell Bio Therapeutics Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, Vaxcell Bio Therapeutics Co reported (5.39 Million) of gross profit. This is much lower than that of the sector and significantly lower than that of the Gross Profit industry. The gross profit for all Republic of Korea stocks is notably higher than that of the company.
Vaxcell-Bio Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Vaxcell-Bio Therapeutics's current stock value. Our valuation model uses many indicators to compare Vaxcell-Bio Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Vaxcell-Bio Therapeutics competition to find correlations between indicators driving Vaxcell-Bio Therapeutics's intrinsic value. More Info.Vaxcell Bio Therapeutics Co is rated below average in return on equity category among its peers. It is the top company in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Vaxcell-Bio Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Vaxcell-Bio Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Vaxcell-Bio Therapeutics Financial Statements
Vaxcell-Bio Therapeutics stakeholders use historical fundamental indicators, such as Vaxcell-Bio Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Vaxcell-Bio Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Vaxcell-Bio Therapeutics' assets and liabilities are reflected in the revenues and expenses on Vaxcell-Bio Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Vaxcell Bio Therapeutics Co. Please read more on our technical analysis and fundamental analysis pages.
Vaxcell-Bio Therapeutics Co., Ltd. develops and sells cancer immune cell therapy products in South Korea. The company was founded in 2010 and is headquartered in Hwasun-eup, South Korea. Vaxcell Bio is traded on Korean Securities Dealers Automated Quotations in South Korea.
Pair Trading with Vaxcell-Bio Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vaxcell-Bio Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vaxcell-Bio Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Vaxcell-Bio Stock
Moving against Vaxcell-Bio Stock
The ability to find closely correlated positions to Vaxcell-Bio Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vaxcell-Bio Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vaxcell-Bio Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vaxcell Bio Therapeutics Co to buy it.
The correlation of Vaxcell-Bio Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vaxcell-Bio Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vaxcell-Bio Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vaxcell-Bio Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Vaxcell-Bio Stock
Vaxcell-Bio Therapeutics financial ratios help investors to determine whether Vaxcell-Bio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Vaxcell-Bio with respect to the benefits of owning Vaxcell-Bio Therapeutics security.